Psychoactive Substances Bill [Lords] Debate
Full Debate: Read Full DebateDavid Burrowes
Main Page: David Burrowes (Conservative - Enfield, Southgate)Department Debates - View all David Burrowes's debates with the Ministry of Justice
(8 years, 10 months ago)
Commons ChamberWe want such places to close down before this Bill is passed. I want this House to send a message to those who are selling these products—head shops or any other premises, or those selling in other ways—that on the day this Bill gets Royal Assent, such selling will become an offence. In saying that, these people have been selling these products perfectly legally for many, many years, so we need to give them an opportunity. This is only part of a process. We are talking about educating the public as well as helping people who are addicted to these substances. At the end of the day, these sellers have to know that, from the day this Bill gets Royal Assent, selling these products is illegal and attracts a seven-year sentence.
I very much commend this Bill. I have been calling for it for many years. The Sentencing Council has an important role to play. Under the Misuse of Drugs Act 1971, sentencing is linked to harm and is commensurate with the offence. At present, there is inequality in sentencing between all types of new psychoactive substances. We need to be clear and link the harm level to the sentence, and that is the important role that the Sentencing Council will have to play.
That important matter was put to me when I gave evidence to the Home Affairs Committee. The difference between what we are doing here and what we are doing with other illegal substances is that this is a blanket ban. If we try to indicate the level of harm on every single one of these substances we will be here forever, which is why we have gone for the blanket ban, and why the Republic of Ireland did the same. As I said to my hon. Friend the Member for North West Hampshire (Kit Malthouse), we will continue to look at this matter, but the guidance to the Sentencing Council is very strong. I am so pleased that the hon. Member for Bassetlaw (John Mann) said that he had been calling for this ban for some time, because I shared an office with my hon. Friend the Member for Enfield, Southgate for five years and I know exactly what his views are. I can genuinely say that apart from a few nuances here and there, most people want to see this Bill on the Statute Book.
I am grateful for the opportunity to contribute to this debate. I very much welcome the Bill.
I am tempted to detain the House for many minutes to respond at length to the hon. Member for Newport West (Paul Flynn), who repeated the same lines that he has for many years. I respect the fact that he is consistent in his liberalising argument. He is now joined by the right hon. Member for North Norfolk (Norman Lamb), who has gone against what his colleagues did in government when they helped prepare the way for this Bill. They both talk about the Advisory Council on the Misuse of Drugs when they choose to. They both talk about relying on the evidence, but they do not do so when it goes against their argument, which is made of straw. They should listen to the evidence given to the Home Affairs Committee. Professor Iversen, the chairman of the ACMD, said that this is the most significant piece of drugs legislation in 40 years, and he and the Committee broadly welcomed it.
There is a consensus in the House that this Bill is not going to prevent everyone from taking NPSs—we all accept that—but it will restrict supply. The Bill is focused on the suppliers of this evil trade. The hon. Member for Newport West talks about a deception. I will tell him what a deception is—it is in any way suggesting that NPSs are legal and safe. That is a deception that has harmed people and led to lost lives, and we are going to tackle it. We are not just going to hold up our hands and make the liberalising arguments saying “Let’s try and do something different.” We need to focus on the supply. This Bill does that, and I welcome it.
Five years ago, on 9 September, I urged the then responsible Minister, my right hon. Friend the Member for Old Bexley and Sidcup (James Brokenshire), to follow the route that has already been trodden by the Irish, recognising that what we have been trying to do in this House, which has been pretty much a useless deception, is to catch up. We have been trying to react to the latest NPS on the market with the temporary class orders that followed on from the advice given by the ACMD, and then we eventually get to the point of having a statutory instrument that is far too late for young people, particularly, in our country. This Bill will at last try to be proactive and respond quickly and expeditiously. What happened in Ireland will happen here.
The Bill says loud and clear that it is calling time on head shops in Bassetlaw and elsewhere and saying very clearly, “Give up, go away—the police are going to come after you and get rid of you. Make sure that you don’t carry on the deception where you are selling these substances used for research on fertilisers, air fresheners and herbal incenses.” That is what I call garbage—not safe garbage but garbage that harms young lives. This approach is worthwhile, but it is not going to solve the problem. There are problems with the internet and with importation and exportation, and we need to do a lot more.
The Bill is not perfect. It needs improvement and scrutiny, particularly in relation to the definition. I declare an interest as a criminal defence lawyer. I want to make sure that my colleagues who are still practising will not be faced with extra loopholes and unintended defences because they are unable to look at the definition as they can now and say, “We are going to have to instruct experts to measure the issue of psychoactivity to assess the behavioural aspects.”
We recognise the example in Ireland, where the Drugs and Organised Crime Bureau has said of the problems with the current definition:
“We are relying on scientists to assist us with these prosecutions and, unfortunately, they haven’t been able to provide the evidence to us.”
We have also listened to the ACMD, which said:
“The only definitive way of determining psychoactivity is via human experience, which is usually not documented.”
I remember my days dealing with the issue of cannabis and its impact on fitness to drive—
Attempting to prove the behavioural impact of cannabis on fitness to drive is subjective and can cause problems. It can result in prosecutions failing and can defeat lawyers and experts. We need to consider the ACMD’s additional recommendation to link the definition of psychoactive to the public health threat. That, together with certain tests included in the Bill, will provide objectivity and clarity.
We need to work on sentences as well as definitions. As I said in an earlier intervention, it is important that someone who is convicted in court is dealt with in a way that is commensurate with their offence. They must be dealt with justly, which means that cases involving controlled drugs should be linked to harm. We need to look carefully at that. The Sentencing Council will have its work cut out, but we should ensure that it is able to play a leading role in ensuring that people are sentenced appropriately. The maximum sentence is seven years, but plainly not everyone who supplies NPSs will face that penalty. In such cases, one usually considers purity as well as the links to harm.
We all agree on education and treatment. Between 2013 and 2015, £180,556 has been spent on NPS education. We need to do better than that. This Bill should spark off further educational investment. Prison education is also important. The Under-Secretary of State for Justice, my hon. Friend the Member for South West Bedfordshire (Andrew Selous), who has responsibility for prisons, is present. I understand that in the past year, 30 ambulances have attended north-west prisons because of NPSs. That is an issue of education as well as of restricting supply. Something is clearly going wrong and it is impacting on our prisons.
On treatment, we visited the drug clinic in Chelsea and Westminster. It is run by the Central and North West London NHS Foundation Trust. Its specialist, bespoke work does a great job of addressing why someone takes a particular drug as well as treating them. That provides a lesson not just for specialist clinics, but for our treatment system, which is behind the times. Gone are the days when we just doled out a substitute drug to treat those addicted to opiates, crack and other controlled drugs. We are talking about the new drug on the market and it is causing harm. We must ensure that the drug treatment system across the country wakes up to the fact that we should deal not just with the substance, but with the addict and provide all the therapeutic support they need and deserve. I hope the Bill will spark off that approach.
I have waited many years for this Bill, as have others. I will not take up any more time. Colleagues who are waiting to go home have been very patient, but I hope they feel that this Bill is worth the wait.
I will be as quick as I can, Mr Deputy Speaker. Like my colleagues, I support the Second Reading of this Bill, but not without a degree of hesitation and of sympathy for the arguments contained in the reasoned amendment. As a member of the Home Affairs Committee, I would like to thank all those who submitted written evidence or gave oral evidence to our short inquiry, and the staff and the former patient of the Club Drug clinic we visited for their constructive and thoughtful criticisms of the Bill. It is fair to say that there was broad, but not unanimous, support for the overarching aims and approach of the legislation.
As the Minister said at the outset, the strategy proposed also had backing from a Scottish Government expert review group and from a report by the Welsh Assembly Health and Social Care Committee. Given that consensus, I agree with my hon. Friend the Member for Glasgow North East (Anne McLaughlin) that it is surprising and a little frustrating—
I believe the Chair of the Home Affairs Committee wanted to make it clear that we know people are waiting for our report and it will be out on Friday in all good shops—and, no doubt, in the Vote Office.
Absolutely. I do not intend to give away any of our conclusions or the recommendations we are going to be making in that report. I am merely referring to evidence that was given in oral sessions or in the written evidence which is freely available.
It is frustrating that we are so far into the legislative process and yet some fundamental questions are still to be resolved. Of course, nothing could be more fundamental than the definition of “psychoactive substance” itself. Addressing that will be the first and most important task of the Public Bill Committee, and it will have to assess whether the definition currently proposed is preferable to that put forward by the ACMD.
A second fundamental problem was highlighted by the evidence provided by both Police Scotland and the Scottish Government on how the current definition of a “psychoactive substance” will require evidence from qualified experts with experience of working with NPSs in order to be able to identify the substance and prove its psychoactivity. Establishing that knowledge base against the background of the fast-paced evolution of psychoactive substances would be difficult, and a constant requirement for expert evidence in court would be very costly. Some of the contradictory reports from Ireland suggest similar problems, and again serious scrutiny of these issues is still required.
Perhaps the most important thing to say about this legislation—we have appreciated this during our inquiry—is, as another hon. Member said, that we cannot see this Bill as a silver bullet. Of far more significance will be the strategies that must be put in place to prevent harm through education and awareness raising, and to intervene where individuals are at risk—that includes the risk that some, but far from all, psychoactive substance users will move to controlled substances or to unregulated dealers. We also need to reduce harm. It is only fair to say that there is a huge distance to travel before we can say that this is being done as well as it must be done. Perhaps in Committee we will be able to consider making information on these matters an express part of the review requirement under clause 57.
In short, this Bill is not a silver bullet—indeed, we could shoot ourselves in the foot if we are not careful to get this right. If the Bill is scrutinised carefully and amended in the light of the evidence, it could be a useful first step in tackling the dangers that many Members have spoken about and that are posed by new psychoactive substances, but the Government need to address the legitimate questions that have been asked tonight. They include questions about the definition, the problems with clause 8, the issue of purchasing for friends, the contradictory evidence from Ireland and the potential for displacement. I wish the Bill Committee well in sorting it all out.